Glenmark Pharmaceuticals Ltd. (GLENMARK.NS), Friday announced that it has introduced Latanoprost Ophthalmic Solution, 0.005 percent, a bioequivalent and therapeutically equivalent alternative to Xalatan Ophthalmic Solution, 0.005 percent, from Upjohn US 2 LLC.
According to IQVIA data, the Xalatan market reached approximately $113.5 million in annual sales for the year ending December 2024.
Glenmark's North America President, Marc Kikuchi, emphasized that this marks the company's fourth ophthalmic product, reinforcing its commitment to expanding its portfolio and delivering high-quality solutions to customers.
GLENMARK.NS closed Friday's trading at INR 1,323.05, down 6.25 percent or INR 88.15 on the National Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.